These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 3976729)
21. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803 [TBL] [Abstract][Full Text] [Related]
22. Cysteamine: new preparation. Chronic treatment of cystinosis. Prescrire Int; 1999 Jun; 8(41):67-70. PubMed ID: 10558441 [TBL] [Abstract][Full Text] [Related]
23. [Distribution of the apolipoprotein-E and -E-complexes in lipoproteins of human serum with the apolipoprotein-E4/E3 phenotype]. Hidaka H; Tozuka M; Yamauchi K; Sugano M; Nakabayashi T; Katsuyama T Rinsho Byori; 1997 Dec; 45(12):1172-6. PubMed ID: 9437899 [TBL] [Abstract][Full Text] [Related]
24. Genetics of type III hyperlipoproteinemia. Feussner G; Piesch S; Dobmeyer J; Fischer C Genet Epidemiol; 1997; 14(3):283-97. PubMed ID: 9181357 [TBL] [Abstract][Full Text] [Related]
25. Treatment of infantile nephropathic cystinosis with cysteamine. N Engl J Med; 1986 May; 314(20):1319-21. PubMed ID: 3702933 [No Abstract] [Full Text] [Related]
26. Genetic polymorphism of apolipoprotein E: a variant form of apolipoprotein E2 distinguished by sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Utermann G; Weisgraber KH; Weber W; Mahley RW J Lipid Res; 1984 Apr; 25(4):378-82. PubMed ID: 6726088 [TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein E phenotype affects the malondialdehyde-modified LDL concentration and forearm endothelial function in postmenopausal women. Tsuda M; Sanada M; Higashi Y; Hara Y; Kodama I; Chayama K; Yoshizumi M; Ohama K Clin Endocrinol (Oxf); 2004 Nov; 61(5):619-25. PubMed ID: 15521966 [TBL] [Abstract][Full Text] [Related]
28. Molecular basis of type III hyperlipoproteinemia in Germany. Feussner G; Feussner V; Hoffmann MM; Lohrmann J; Wieland H; März W Hum Mutat; 1998; 11(6):417-23. PubMed ID: 9603433 [TBL] [Abstract][Full Text] [Related]
29. [Apolipoproteins and atherosclerosis--study of apolipoprotein E]. Taniguchi T; Yamasaki S Rinsho Byori; 1984 Jul; 32(7):772-9. PubMed ID: 6389939 [No Abstract] [Full Text] [Related]
31. Approaches to the treatment of inborn errors of sulphur amino acid and peptide metabolism. Schulman JD Prog Clin Biol Res; 1979; 34():201-15. PubMed ID: 531052 [No Abstract] [Full Text] [Related]
32. [The treatment of cystinosis with cysteamine]. Cantani A; Giardini O; D'Eufemia P Ann Pediatr (Paris); 1991 Jun; 38(6):440. PubMed ID: 1929112 [No Abstract] [Full Text] [Related]
33. Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Hoffer MJ; Niththyananthan S; Naoumova RP; Kibirige MS; Frants RR; Havekes LM; Thompson GR Atherosclerosis; 1996 Aug; 124(2):183-9. PubMed ID: 8830931 [TBL] [Abstract][Full Text] [Related]
34. Characterisation and mode of inheritance of apolipoprotein E3-Leiden. Havekes L; Utermann G; de Knijff P; Klasen E Adv Exp Med Biol; 1987; 210():41-5. PubMed ID: 3591555 [No Abstract] [Full Text] [Related]
35. Plasma cysteamine concentrations in children treated for cystinosis. Jonas AJ; Schneider JA J Pediatr; 1982 Feb; 100(2):321-3. PubMed ID: 7057343 [No Abstract] [Full Text] [Related]
36. Cysteamine toxicity in patients with cystinosis. Besouw MT; Bowker R; Dutertre JP; Emma F; Gahl WA; Greco M; Lilien MR; McKiernan J; Nobili F; Schneider JA; Skovby F; van den Heuvel LP; Van't Hoff WG; Levtchenko EN J Pediatr; 2011 Dec; 159(6):1004-11. PubMed ID: 21784456 [TBL] [Abstract][Full Text] [Related]